Related Experiment Videos

Antitumor action of an acidic glycoprotein (SAGP) from Streptococcus pyogenes in mice

J Yoshida1, S Takamura, S Suzuki

  • 1Department of Pharmacology, Kanazawa Medical University, Ishikawa, Japan.

Biotherapy (Dordrecht, Netherlands)
|January 1, 1991
PubMed

Insights

An acidic glycoprotein (SAGP) from Streptococcus pyogenes extends mouse lifespan against cancer. Its antitumor effects appear mediated by immune system modulation, as shown by reduced efficacy with X-irradiation and carrageenan treatment.

Area of Science:

  • Immunology
  • Oncology
  • Microbiology

Background:

  • An acidic glycoprotein (SAGP) from Streptococcus pyogenes demonstrates life-extending properties in cancer models.
  • Previous research indicated SAGP's efficacy in prolonging survival in Ehrlich ascites carcinoma (EAC)-bearing mice.

Purpose of the Study:

  • To investigate the mechanism behind the in vivo antitumor effects of SAGP.
  • To determine if SAGP's efficacy is dependent on immune system function.

Main Methods:

  • Ehrlich ascites carcinoma (EAC) and Meth A fibrosarcoma (Meth A) mouse models were utilized.
  • SAGP efficacy was assessed following whole-body X-irradiation and carrageenan pretreatment.
  • Spleen cell cytostatic activity was measured using a 3H-thymidine incorporation assay.

Main Results:

  • X-irradiation significantly reduced SAGP's life-prolonging effect in EAC-bearing mice.
  • Carrageenan, an antimacrophage agent, abrogated SAGP's efficacy in Meth A-bearing mice.
  • Spleen cells from SAGP-treated mice exhibited cytostatic activity, which was abolished by carrageenan.

Conclusions:

  • The in vivo antitumor effects of SAGP are likely mediated by its immunomodulating actions.
  • SAGP's efficacy appears to be dependent on macrophage activity and overall immune response.

Related Concept Videos